Duravyu missed wet AMD noninferiority twice, DAYBREAK met its end points, and optogenetics won the Nobel as son-vec posted ...
Technician-led screening catches hidden ocular surface disease before cataract surgery and helps decide when to delay surgery ...
Uday Devgan, MD, FACS, Jordana G. Fein, MD, MS, and Carl D. Regillo, MD, FASRS, point to IOL education, emerging retina therapies, and treatment burden.
Murtaza K. Adam, MD, reviews 3 patient cases to explore referral patterns, neovascularization after treatment, and barriers to care.
Carreño discusses oral protein-folding correction for RHO-adRP, early-phase trial end points and genetic eligibility.
Eye care providers urged FDA advisers to approve SYD-101, citing myopia’s lifelong risks, compounding gaps and STAR trial ...
An estimated 9.6 million people in the US have diabetic retinopathy, and roughly 1 in 3 patients with diabetes miss annual ...
Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.
Luma, an eye-tracking and assessment tool, helps eye care professionals gain objective insights into visual performance.
Jordana G. Fein, MD, MS, points to agent selection, payer requirements, and real-world treatment response across 3 retina ...
In more than 90,000 people across TWO independent cohorts, those with atrial fibrillaion (AF) had a thinner macular ganglion ...
Eleonora Lad, MD, PhD, Dimitra Skondra, MD, PhD, and John Kitchens, MD, point to structure and function, diet and the gut, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results